Sugi Predict

Sugi Predict / Compounds / SCHEMBL3355665

SCHEMBL3355665

SCHEMBL3355665

CN1CC(C(=O)O)Oc2ccc(Cl)cc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.66
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ ALDH1A1 P00352 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CYP2C9 P11712 3/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ CYP3A4 P08684 2/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ CYP2D6 P10635 1/20 0.48
▸ NISCH Q9Y2I1 1/20 0.48
▸ MAPT P10636 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HRH2 P25021 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ CPT1A P50416 3/20 0.45
▸ CPT1B Q92523 3/20 0.45
▸ TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29527101 1.00 POLB (0.66) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL22777623 0.83 POLB (0.60) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL924610 0.82 POLB (0.46) POLBMEN1KMT2AALDH1A1CYP2C9
SCHEMBL17443415 0.82 NISCH (0.48) POLBMEN1KMT2AALDH1A1CYP2C9
SCHEMBL23920645 0.82 CYP1A2 (0.72) POLBKMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL925260 0.81 SIRT1 (0.48) POLBKMT2AALDH1A1SMN1; SMN2CYP2C9
SCHEMBL7818287 0.81 POLB (0.73) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL22397094 0.80 POLB (0.54) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL3353292 0.80 POLB (0.62) POLBMEN1KMT2AMAPTTP53
SCHEMBL537789 0.79 POLB (0.53) POLBMEN1KMT2AALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018133-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-01-18 — — US disclosed
US-20240000792-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC 2024-01-04 — — US disclosed
CN-114401952-A Substituted cycloalkyl compounds as modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-04-26 — — CN disclosed
EP-3983378-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC (US) 2022-04-20 — — EP disclosed
EP-3962899-A1 SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2022-03-09 — — EP disclosed
US-20210363136-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2021-11-25 — — US disclosed
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2021-10-14 — — US disclosed
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2021-10-14 — — US disclosed
US-20210253528-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
US-20210253528-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
EP-3820843-A1 CHEMICAL COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-05-19 — — EP disclosed
CN-112424167-A Chemical compound 葛兰素史密斯克莱知识产权发展有限公司 2021-02-26 — — CN disclosed
CN-112218850-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2021-01-12 — — CN disclosed
WO-2020252205-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC (US) 2020-12-17 — — WO disclosed
WO-2020223536-A1 SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2020-11-05 — — WO disclosed
EP-3704090-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2020-09-09 — — EP disclosed
WO-2020012339-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-01-16 — — WO disclosed
WO-2020012339-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-01-16 — — WO disclosed
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-06-17 — — US disclosed
WO-2010068881-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210363136-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 POLB 1759/4885MEN1 4729/4885KMT2A 4313/4885
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 POLB 1498/4885MEN1 4345/4885KMT2A 4528/4885
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS CCR1, CCR4, CCR5 POLB 3780/4885MEN1 4595/4885KMT2A 3495/4885
US-20240018133-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 POLB 1759/4885MEN1 4729/4885KMT2A 4313/4885
US-20210253528-A1 CHEMICAL COMPOUNDS ATF4, EIF2AK4, ATF1 POLB 4266/4885MEN1 3941/4885KMT2A 4235/4885
US-20240000792-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 POLB 1759/4885MEN1 4729/4885KMT2A 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.